Related references
Note: Only part of the references are listed.Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current
Ruth Sittl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
D. J. Storey et al.
ANNALS OF ONCOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools
Guido Cavaletti et al.
EUROPEAN JOURNAL OF CANCER (2010)
Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?
A. G. Antonacopoulou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
Kyung Kee Baek et al.
CANCER RESEARCH AND TREATMENT (2010)
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
M. L. Rothenberg et al.
ANNALS OF ONCOLOGY (2008)
A review on oxaliplatin-induced peripheral nerve damage
Andreas A. Argyriou et al.
CANCER TREATMENT REVIEWS (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Vassilis Golfinopoulos et al.
LANCET ONCOLOGY (2007)
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
Guido Cavaletti et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2007)
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
Stephanie R. Land et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer
Andreas A. Argyriou et al.
ACTA ONCOLOGICA (2007)
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin-related neurotoxicity: How and why?
Lara Maria Pasetto et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity
G Cavaletti et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2006)
Adjuvant therapy in colon cancer - what, when and how?
I. Chau et al.
ANNALS OF ONCOLOGY (2006)
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer
Roberto Petrioli et al.
ONCOLOGY (2006)
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
HP Kalofonos et al.
ANNALS OF ONCOLOGY (2005)
A review of oxaliplatin and its clinical use in colorectal cancer
A Grothey et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Peripheral neuropathy associated with capecitabine
MW Saif et al.
ANTI-CANCER DRUGS (2004)
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
F Maindrault-Goebel et al.
ANNALS OF ONCOLOGY (2004)
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer
N Kemeny et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
G Cavaletti et al.
EUROPEAN JOURNAL OF CANCER (2001)
Peripheral neuropathy associated with weekly oval 5-fluorouvacil, leucovorin and eniluracil
MW Saif et al.
ANTI-CANCER DRUGS (2001)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
